IRIDEX Reports Strong Attendance at European Workshop for its Proprietary MicroPulse® Laser Therapy for Retina and Glaucoma Applications

MOUNTAIN VIEW, Calif., Oct. 1, 2014 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today reported a strong physician presence and reception at this year's joint congress of the European Society of Retina Specialists (EURETINA) and European Society of Cataract and Refractive Surgeons (ESCRS) meeting in London.  Among its activities at the event, IRIDEX hosted a workshop on its MicroPulse Laser Therapy to a standing room only auditorium – over 150 physicians were in attendance.  In addition, the EURETINA society independently hosted an official instructional course on MicroPulse technology as part of its society curriculum.

Three leading ophthalmic physicians led the workshop that included the latest MicroPulse-related techniques for the treatment of glaucoma and diabetes-related retinal disease.  In addition, the physicians offered their views on the compelling need to provide MicroPulse Laser Therapy to their patients. The panelists were: Robert Noecker, MD of Ophthalmic Consultants of Connecticut and Assistant Clinical Professor at Yale University; retina specialist Stela Vujosevic, MD, Ph.D. of the University of Padova in Italy; and retina specialist Adam Rogers, MD of the New England Eye Center and Assistant Professor at Tufts University in Boston.

"The durable clinical effect in retinal procedures, combined with a growing body of new data in treating glaucoma further validates MicroPulse Laser Therapy and its prominent role within the global trend towards value-based medicine," said Will Moore, IRIDEX President and CEO.  "It was especially encouraging to note that, in an audience poll, a majority of the physicians in attendance identified themselves as interested in learning more about MicroPulse and potentially becoming customers."

Link to EyeWorld Video Feature – Glaucoma specialist - Robert Noecker, MD, MBA http://bit.ly/1xpSP6l.

About IRIDEX 
IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The company maintains a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through both direct and independent sales forces and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the company's website at http://www.iridex.com.

Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning the adoption of and demand for MicroPulse Laser Therapy and related trends in treatment and product usage. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 28, 2013, which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

Logo - http://photos.prnewswire.com/prnh/20141001/149809

SOURCE IRIDEX Corporation